General References


Václavíková R, Horský S, Simek P, Gut I. Paclitaxel metabolism in rat and human liver microsomes is inhibited by phenolic antioxidants. Naunyn Schmiedebergs Arch Pharmacol 2003; 368:200-9.

Václavíková R, Hubackova M, Stribrna-Sarmanova J et al. RNA expression of cytochrome P450 in breast cancer patients. Anticancer Res 2007; 27:4443-50.

Vaclavikova R, Nordgard SH, Alnaes GI et al. Single nucleotide polymorphisms in the multidrug resistance gene 1 (ABCB1): effects on its expression and clinicopathological characteristics in breast cancer patients. Pharmacogenet Genomics 2008; 18:263-73.

Václavíková R, Soucek P, Svobodova L et al. Different in vitro metabolism of paclitaxel and docetaxel in humans, rats, pigs, and minipigs. Drug Metab Dispos 2004; 32:666-74.

Vader W, Stepniak D, Kooy Y et al. The HLA-DQ2 gene dose effect in celiac disease is directly related to the magnitude and breadth of gluten-specific T cell responses. Proc Natl Acad Sci USA 2003; 100:12390-5.

Vähäkangas K, Myllynen P. Drug transporters in the human blood-placental barrier. Br J Pharmacol 2009; 158:665-78.

Vaidya SS, Walsh SW, Gerk PM. Application of human placental villous tissue explants to study ABC transporter mediated efflux of 2,4-Dinitrophenyl-S-Glutathione. Curr Pharm Biotechnol 2011; 12:814-23.

Vaidyanathan S, Camenisch G, Schuetz H et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. J Clin Pharmacol 2008; 48:1323-38.

Vaishampayan U, Hussain M, Banerjee M et al. Lycopene and soy isoflavones in the treatment of prostate cancer. Nutr Cancer 2007; 59:1-7.

Vakily M, Lee RD, Wu J, Gunawardhana L, Mulford D. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies. Clin Drug Investig 2009; 29:35-50.

Valcke M, Krishnan K. An assessment of the impact of physico-chemical and biochemical characteristics on the human kinetic adjustment factor for systemic toxicants. Toxicology 2011; 286:36-47.

Valenti L, Valenti G, Como G et al. HFE genotype influences erythropoiesis support requirement in hemodialysis patients: a prospective study. Am J Nephrol 2008; 28:311-6.

Valentine CR, Valentine JL, Seng J, Leakey J, Casciano D. The use of transgenic cell lines for evaluating toxic metabolites of carbamazepine. Cell Biol Toxicol 1996; 12:155-65.

Valenzuela B, López-Pintor E, Pérez-Ruixo JJ, Nácher A, Martín-Villodre A, Casabó VG. Modelling intestinal absorption of salbutamol sulphate in rats. Int J Pharm 2006; 314:21-30.

Valenzuela N. Multivariate expression analysis of the gene network underlying sexual development in turtle embryos with temperature-dependent and genotypic sex determination. Sex Dev 2010; 4:39-49.

Valenzuela OL, Drobná Z, Hernández-Castellanos E et al. Association of AS3MT polymorphisms and the risk of premalignant arsenic skin lesions. Toxicol Appl Pharmacol 2009; 239:200-7.

Valera ET, de Freitas Cortez MA, de Paula Queiroz RG et al. Pediatric glioblastoma cell line shows different patterns of expression of transmembrane ABC transporters after in vitro exposure to vinblastine. Childs Nerv Syst 2009; 25:39-45.

Valkenburg O, Uitterlinden AG, Themmen AP et al. Genetic polymorphisms of the glucocorticoid receptor may affect the phenotype of women with anovulatory polycystic ovary syndrome. Hum Reprod 2011; 26:2902-11.

Valoti M, Fusi F, Frosini M, Pessina F, Tipton KF, Sgaragli GP. Cytochrome P450-dependent N-dealkylation of L-deprenyl in C57BL mouse liver microsomes: effects of in vivo pretreatment with ethanol, phenobarbital, beta-naphthoflavone and L-deprenyl. Eur J Pharmacol 2000; 391:199-206.

Valve R, Sivenius K, Miettinen R et al. Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. J Clin Endocrinol Metab 1999; 84:3708-12.

Valverde P, Healy E, Jackson I, Rees JL, Thody AJ. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 1995; 11:328-30.

Valverde P, Healy E, Sikkink S et al. The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. Hum Mol Genet 1996; 5:1663-6.

Vallakati A, Chandra PA, Pednekar M, Frankel R, Shani J. Dronedarone-induced digoxin toxicity: new drug, new interactions. Am J Ther 2011. doi:10. 1097/MJT. 0b013e31821106c9.

Vallcaneras SS, Casais M, Anzulovich AC et al. Androstenedione acts on the coeliac ganglion and modulates luteal function via the superior ovarian nerve in the postpartum rat. J Steroid Biochem Mol Biol 2011; 125:243-50.

Valle AM, Radic Z, Rana BK et al. The cholinesterases: analysis by pharmacogenomics in man. Chem Biol Interact 2008; 175:343-5.

Valle JW, Armstrong A, Newman C et al. A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Invest New Drugs 2011; 29:1029-37.

Valles B, Schiller CD, Coassolo P et al. Metabolism of mofarotene in hepatocytes and liver microsomes from different species. Comparison with in vivo data and evaluation of the cytochrome P450 isoenzymes involved in human biotransformation. Drug Metab Dispos 1995; 23:1051-7.

Valles J, Artigas R, Mas M et al. Pharmacokinetics of dexketoprofen trometamol in subjects with mild and moderate chronic renal insufficiency. Methods Find Exp Clin Pharmacol 2006; 28 Suppl A:21-8.

van Aalst-Cohen ES, Jansen AC, Boekholdt SM et al. Genetic determinants of plasma HDL-cholesterol levels in familial hypercholesterolemia. Eur J Hum Genet 2005; 13:1137-42.

van Agthoven T, Sieuwerts AM, Meijer-van Gelder ME et al. Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. J Clin Oncol 2009; 27:542-9.

van Agthoven T, Veldscholte J, Smid M et al. Functional identification of genes causing estrogen independence of human breast cancer cells. Breast Cancer Res Treat 2009; 114:23-30.

van Agtmael MA, Gupta V, van der Graaf CA, van Boxtel CJ. The effect of grapefruit juice on the time-dependent decline of artemether plasma levels in healthy subjects. Clin Pharmacol Ther 1999; 66:408-14.

van Agtmael MA, Gupta V, van der Wösten TH, Rutten JP, van Boxtel CJ. Grapefruit juice increases the bioavailability of artemether. Eur J Clin Pharmacol 1999; 55:405-10.

van Aubel RA, Smeets PH, Peters JG, Bindels RJ, Russel FG. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol 2002; 13:595-603.

van Belzen MJ, Meijer JW, Sandkuijl LA et al. A major non-HLA locus in celiac disease maps to chromosome 19. Gastroenterology 2003; 125:1032-41.

van Bemmel DM, Li Y, McLean J et al. Blood lead levels, ALAD gene polymorphisms, and mortality. Epidemiology 2011; 22:273-8.

van Bockxmeer FM, Mamotte CD, Vasikaran SD, Taylor RR. Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation 1997; 95:21-3.

van Breemen RB, Li Y. Caco-2 cell permeability assays to measure drug absorption. Expert Opin Drug Metab Toxicol 2005; 1:175-85.

van de Kerkhof EG, de Graaf IA, Ungell AL, Groothuis GM. Induction of metabolism and transport in human intestine: validation of precision-cut slices as a tool to study induction of drug metabolism in human intestine in vitro. Drug Metab Dispos 2008; 36:604-13.

van de Parre TJ, Guns PJ, Fransen P et al. Attenuated atherogenesis in apolipoprotein E-deficient mice lacking amyloid precursor protein. Atherosclerosis 2011; 216:54-8.

van de Poll ME, Relling MV, Schuetz EG, Harrison PL, Hughes W, Flynn PM. The effect of atovaquone on etoposide pharmacokinetics in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 2001; 47:467-72.

van de Sande WW, Fahal A, Tavakol M, van Belkum A. Polymorphisms in catechol-O-methyltransferase and cytochrome p450 subfamily 19 genes predispose towards Madurella mycetomatis-induced mycetoma susceptibility. Med Mycol 2010; 48:959-68.

van de Steeg E, van der Kruijssen CM, Wagenaar E et al. Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1). Drug Metab Dispos 2009; 37:277-81.

van de Ven R, de Groot J, Reurs AW et al. Unimpaired immune functions in the absence of Mrp4 (Abcc4). Immunol Lett 2009; 124:81-7.

van de Ven R, Lindenberg JJ, Reurs AW, Scheper RJ, Scheffer GL, de Gruijl TD. Preferential Langerhans cell differentiation from CD34(+) precursors upon introduction of ABCG2 (BCRP). Immunol Cell Biol 2011. doi:10. 1038/icb. 2011. 25.

van de Vosse E, de Visser AW, Al-Attar S, Vossen R, Ali S, van Dissel JT. Distribution of CFTR variations in an Indonesian enteric fever cohort. Clin Infect Dis 2010; 50:1231-7.

van de Vrugt HJ, Eaton L, Hanlon Newell A et al. Embryonic lethality after combined inactivation of Fancd2 and Mlh1 in mice. Cancer Res 2009; 69:9431-8.

van Dellen A, Blakemore C, Deacon R, York D, Hannan A. Delaying the onset of Huntington’s in mice: this unremitting disease develops later in animals stimulated by their environment. Nature 2000; 404:721-2.

van den Bogaert A, Schumacher J, Schulze TG et al. The DTNBP1 (dysbindin) gene contributes to schizophrenia, depending on family history of the disease. Am J Hum Genet 2003; 73:1438-43.

van den Bongard HJ, Sparidans RW, Critchley DJ, Beijnen JH, Schellens JH. Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol. Invest New Drugs 2004; 22:151-8.

van den Born BJ, van Montfrans GA, Uitterlinden AG, Zwinderman AH, Koopmans RP. The M235T polymorphism in the angiotensinogen gene is associated with the risk of malignant hypertension in white patients. J Hypertens 2007; 25:2227-33.

van den Bout-van den Beukel CJ, Hamza OJ, Moshi MJ et al. Evaluation of cytotoxic, genotoxic and CYP450 enzymatic competition effects of Tanzanian plant extracts traditionally used for treatment of fungal infections. Basic Clin Pharmacol Toxicol 2008; 102:515-26.

van den Elzen P, Garg S, Leon L et al. Apolipoprotein-mediated pathways of lipid antigen presentation. Nature 2005; 437:906-10.

van den Kommer TN, Dik MG, Comijs HC et al. The role of extracerebral cholesterol homeostasis and ApoE e4 in cognitive decline. Neurobiol Aging 2011. doi:10. 1016/j. neurobiolaging. 2011. 02. 019.

van den Oord EJ, Sullivan PF, Jiang Y et al. Identification of a high-risk haplotype for the dystrobrevin binding protein 1 (DTNBP1) gene in the Irish study of high-density schizophrenia families. Mol Psychiatry 2003; 8:499-510.

van der Bol JM, Loos WJ, de Jong FA et al. Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction study. Eur J Cancer 2011; 47:831-8.

van der Bol JM, Mathijssen RH, Creemers GJ et al. A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. Clin Cancer Res 2010; 16:736-42.

van der Deure WM, Appelhof BC, Peeters RP et al. Polymorphisms in the brain-specific thyroid hormone transporter OATP1C1 are associated with fatigue and depression in hypothyroid patients. Clin Endocrinol 2008; 69:804-11.

van der Heijden MS, Brody JR, Dezentje DA et al. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res 2005; 11:7508-15.

van der Heyden S, Vercauteren G, Daminet S et al. Expression of P-glycoprotein in the intestinal epithelium of dogs with lymphoplasmacytic enteritis. J Comp Pathol 2011; 145:199-206.

van der Holt B, van den Heuvel-Eibrink MM, van Schaik RH et al. ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients. Clin Pharmacol Ther 2006; 80:427-39.

van der Hoorn J, Lindén D, Lindahl U et al. Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE*3Leiden mice without affecting liver or plasma triglyceride levels. Br J Pharmacol 2011; 162:1553-63.

van der Klaauw AA, van der Straaten T, Baak-Pablo R et al. Influence of the d3-growth hormone (GH) receptor isoform on short-term and long-term treatment response to GH replacement in GH-deficient adults. J Clin Endocrinol Metab 2008; 93:2828-34.

van der Kuy PH, van den Heuvel HA, Kempen RW, Vanmolkot LM. Pharmacokinetic interaction between nortriptyline and terbinafine. Ann Pharmacother 2002; 36:1712-4.

van der Lee MJ, Blenke AA, Rongen GA et al. Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects. Antimicrob Agents Chemother 2007; 51:4098-104.

van der Logt EM, Bergevoet SM, Roelofs HM et al. Genetic polymorphisms in UDP-glucuronosyltransferases and glutathione S-transferases and colorectal cancer risk. Carcinogenesis 2004; 25:2407-15.

van der Meer IM, Witteman JC, Hofman A, Kluft C, de Maat MP. Genetic variation in Fcgamma receptor IIa protects against advanced peripheral atherosclerosis. The Rotterdam Study. Thromb Haemost 2004; 92:1273-6.

van der Padt A, van Schaik RH, Sonneveld P. Acute dystonic reaction to metoclopramide in patients carrying homozygous cytochrome P450 2D6 genetic polymorphisms. Neth J Med 2006; 64:160-2.

van der Put NM, Gabreëls F, Stevens EM et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 1998; 62:1044-51.

van der Straaten RJ, Wessels JA, de Vries-Bouwstra JK et al. Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients. Pharmacogenomics 2007; 8:141-50.

van der Velden W, Huussen J, Ter Laak H, de Sévaux R. Colchicine-induced neuromyopathy in a patient with chronic renal failure: the role of clarithromycin. Neth J Med 2008; 66:204-6.

van der Veldt AA, Eechoute K, Gelderblom H et al. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res 2011; 17:620-9.

van der Weide J, Hinrichs JW. The influence of cytochrome P450 pharmacogenetics on disposition of common antidepressant and antipsychotic medications. Clin Biochem Rev 2006; 27:17-25.

van der Weide J, Steijns LS, van Weelden MJ, de Haan K. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics 2001; 11:287-91.

van der Weide J, van Baalen-Benedek EH, Kootstra-Ros JE. Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype. Ther Drug Monit 2005; 27:478-83.

van Dijk EJ, Prins ND, Vermeer SE et al. Plasma amyloid beta, apolipoprotein E, lacunar interfacts, and white matter lesions. Ann Neurol 2004; 55:570-5.

van Dijk J, van der Velde E, Ross R, Bruyn G. Juvenile Huntington disease. Hum Genet 1986; 73:235-9.

van Doren M, Broihier HT, Moore LA, Lehmann R. HMG-CoA reductase guides migrating primordial germ cells. Nature 1998; 396:466-9.

van Driel LM, Smedts HP, Helbing WA et al. Eight-fold increased risk for congenital heart defects in children carrying the nicotinamide N-methyltransferase polymorphism and exposed to medicines and low nicotinamide. Eur Heart J 2008; 29:1424-31.

van Duijnhoven EM, Boots JM, Christiaans MH, Stolk LM, Undre NA, van Hooff JP. Increase in tacrolimus trough levels after steroid withdrawal. Transpl Int 2003; 16:721-5.

van Dujin CM, de Knijff P, Cruts M et al. Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer’s disease. Nat Genet 1994; 7:74-8.

van Duursen MB, Nijmeijer SM, de Morree ES, de Jong PC, van den Berg M. Genistein induces breast cancer-associated aromatase and stimulates estrogen-dependent tumor cell growth in in vitro breast cancer model. Toxicology 2011; 289:67-73.

van Ede AE, Laan RF, de Abreu RA, Stegeman AB, van de Putte LB. Purine enzymes in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis 2002; 61:1060-4.

van Erp N, Gelderblom H, van Glabbeke M et al. Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC. Clin Cancer Res 2008; 14:8308-13.

van Erp NP, Baker SD, Zhao M et al. Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. Clin Cancer Res 2005; 11:7800-6.

van Erp NP, Eechoute K, van der Veldt AA et al. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol 2009; 27:4406-12.

van Erp NP, Gelderblom H, Karlsson MO et al. Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. Clin Cancer Res 2007; 13:7394-400.

van Es T, van Puijvelde GH, Ramos OH et al. Attenuated atherosclerosis upon IL-17R signaling disruption in LDLr deficient mice. Biochem Biophys Res Commun 2009; 388:261-5.

van Eyken E, van Camp G, Fransen E et al. Contribution of the N-acetyltransferase 2 polymorphism NAT2*6A to age-related hearing impairment. J Med Genet 2007; 44:570-8.

van Geel PP, Pinto YM, Buikema H, van Gilst WH. Is the A1166C polymorphism of the angiotensin II type 1 receptor involved in cardiovascular disease? Eur Heart J 1998; 19 Suppl G:13-7.

van Geel PP, Pinto YM, Zwinderman AH et al. Increased risk for ischaemic events is related to combined RAS polymorphism. Heart 2001; 85:458-62.

van Giersbergen PL, Gnerre C, Treiber A, Dingemanse J, Meyer UA. Bosentan, a dual endothelin receptor antagonist, activates the pregnane X nuclear receptor. Eur J Pharmacol 2002; 450:115-21.

van Giersbergen PL, Halabi A, Dingemanse J. Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. Br J Clin Pharmacol 2002; 53:589-95.

van Giersbergen PL, Halabi A, Dingemanse J. Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol. Int J Clin Pharmacol Ther 2006; 44:113-8.

van Giersbergen PL, Treiber A, Clozel M, Bodin F, Dingemanse J. In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide. Clin Pharmacol Ther 2002; 71:253-62.

van Giersbergen PL, Treiber A, Schneiter R, Dietrich H, Dingemanse J. Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects. Clin Pharmacol Ther 2007; 81:414-9.

van Goethem G, Dermaut B, Lofgren A, Martin J-J, van Broeckhoven C. Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions. Nat Genet 2001; 28:211-2.

van Goethem G, Löfgren A, Dermaut B et al. Digenic progressive external ophthalmoplegia in a sporadic patient: recessive mutations in POLG and C10orf2/Twinkle. Hum Mutat 2003; 22:175-6.

van Goethem G, Luoma P, Rantamäki M et al. POLG mutations in neurodegenerative disorders with ataxia but no muscle involvement. Neurology 2004; 63:1251-7.

van Goethem G, Martin JJ, Dermaut B et al. Recessive POLG mutations presenting with sensory and ataxic neuropathy in compound heterozygote patients with progressive external ophthalmoplegia. Neuromuscul Disord 2003; 13:133-42.

van Goethem G, Mercelis R, Löfgren A et al. Patient homozygous for a recessive POLG mutation presents with features of MERRF. Neurology 2003; 61:1811-3.

van Goethem G, Schwartz M, Löfgren A, Dermaut B, van Broeckhoven C, Vissing J. Novel POLG mutations in progressive external ophthalmoplegia mimicking mitochondrial neurogastrointestinal encephalomyopathy. Eur J Hum Genet 2003; 11:547-9.

van Gool WA, Evenhuis HM, van Duijin CM. A case-control study of apolipoprotein E genotypes in Alzheimer’s disease associated with Down’s syndrome. Ann Neurol 1995; 38:225-30.

van Harten J. Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet 1995; 29 Suppl 1:1-9.

van Hee VC, Adar SD, Szpiro AA et al. Common genetic variation, residential proximity to traffic exposure, and left ventricular mass: the multi-ethnic study of atherosclerosis. Environ Health Perspect 2010; 118:962-9.

van Heel DA, Franke L, Hunt KA et al. A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat Genet 2007; 39:827-9.

van Heeswijk RP, Cooper CL, Foster BC et al. Effect of high-dose vitamin C on hepatic cytochrome P450 3A4 activity. Pharmacotherapy 2005; 25:1725-8.

van Heeswijk RP, Veldkamp A, Mulder JW et al. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience. Antivir Ther 2001; 6:201-29.

van Herwaarden AE, Smit JW, Sparidans RW et al. Midazolam and cyclosporin a metabolism in transgenic mice with liver-specific expression of human CYP3A4. Drug Metab Dispos 2005; 33:892-5.

van Herwaarden AE, van Waterschoot RA, Schinkel AH. How important is intestinal cytochrome P450 3A metabolism? Trends Pharmacol Sci 2009; 30:223-7.

van Herwaarden AE, Wagenaar E, van der Kruijssen CM et al. Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest 2007; 117:3583-92.

van Hooft IM, Grobbee DE, Derkx FH, de Leeuw PW, Schalekamp MA, Hofman A. Renal hemodynamics and the renin-angiotensin-aldosterone system in normotensive subjects with hypertensive and normotensive parents. N Engl J Med 1991; 324:1305-11.

van Ittersum FJ, de Man AM, Thijssen S et al. Genetic polymorphisms of the renin-angiotensin system and complications of insulin-dependent diabetes mellitus. Nephrol Dial Transplant 2000; 15:1000-7.

van Kuijck MA, Kool M, Merkx GFM et al. Assignment of the canalicular multispecific organic anion transporter gene (CMOAT) to human chromosome 10q24 and mouse chromosome 19D2 by fluorescent in situ hybridization. Cytogenet Cell Genet 1997; 77:285-7.

van Kuilenburg AB, de Abreu RA, van Gennip AH. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency. Ann Clin Biochem 2003; 40:41-5.

van Kuilenburg AB, Meijer J, Dobritzsch D et al. Clinical, biochemical and genetic findings in two siblings with a dihydropyrimidinase deficiency. Mol Genet Metab 2007; 91:157-64.

van Kuilenburg AB, Meijer J, Dobritzsch D et al. Identification of two novel mutations C79X and R235Q in the dihydropyrimidine dehydrogenase gene in a patient presenting with hematuria. Nucleosides Nucleotides Nucleic Acids 2008; 27:809-15.

van Kuilenburg AB, Meijer J, Mul AN et al. Analysis of severely affected patients with dihydropyrimidine dehydrogenase deficiency reveals large intragenic rearrangements of DPYD and a de novo interstitial deletion del(1)(p13. 3p21. 3). Hum Genet 2009; 125:581-90.

van Kuilenburg AB, Meinsma R, Zoetekouw L, van Gennip AH. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 2002; 12:555-8.

van Kuilenburg ABP, van Lenthe H, Blom MJ, Mul EPJ, van Gennip AH. Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients. Brit J Cancer 1999; 79:620-6.

van Laer L, Carlsson PI, Ottschytsch N et al. The contribution of genes involved in potassium-recycling in the inner ear to noise-induced hearing loss. Hum Mutat 2006; 27:786-95.

van Leeuwen FW. Neuropeptide research discloses part of the secrets of Alzheimer’s disease neuropathogenesis: state of the art 2004. Neurosci Lett 2004; 361:124-7.

van Leeuwen FW, Burbach JP, Hol EM. Mutations in RNA: a first example of molecular misreading in Alzheimer’s disease. Trends Neurosci 1998; 21:331-5.

van Leeuwen FW, de Kleijn DPV, van de Hurk HH et al. Frameshift mutants of beta-amyloid precursor protein and ubiquitin-B in Alzheimer’s and Down patients. Science 1998; 279:242-7.

van Leeuwen FW, Fisher DF, Kamel D et al. Molecular misreading: a new type of transcript mutation expressed during aging. Neurobiol. Aging 2000; 21:879-91.

Van LM, Hargreaves JA, Lennard MS, Tucker GT, Rostami-Hodjegan A. Inactivation of CYP2D6 by methylenedioxymethamphetamine in different recombinant expression systems. Eur J Pharm Sci 2007; 32:8-16.

van Maldergem L. Berardinelli-Seip congenital lipodystrophy. In: Pagon RA, Bird TC, Dolan CR, Stephens K (Eds). GeneReviews. University of Washington, Seattle, 1993-2003. Available from: http://www. ncbi. nlm. nih. gov/books/NBK1212/

van Manen D, Kootstra NA, Boeser-Nunnink B, Handulle MA, van’t Wout AB, Schuitemaker H. Association of HLA-C and HCP5 gene regions with the clinical course of HIV-1 infection. AIDS 2009; 23:19-28.

van Marle S, van Vliet A, Sollie F, Kambayashi Y, Yamada-Sawada T. Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. Int J Clin Pharmacol Ther 2005; 43:282-93.

van Ness B, Ramos C, Haznadar M et al. Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival. BMC Med 2008; 6:26.

van Nieuwerburgh FC, Denys DA, Westenberg HG, Deforce DL. Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms. Int J Psychiatry Clin Pract 2009; 13:345-8.

van Ree JH, van den Broek WJJA, van der Zee A et al. Inactivation of Apoe and Apoc1 by two consecutive rounds of gene targeting: effects on mRNA expression levels of gene cluster members. Hum Molec Genet 1995; 4:1403-9.

van Rijn MJ, Bos MJ, Yazdanpanah M et al. Alpha-adducin polymorphism, atherosclerosis, and cardiovascular and cerebrovascular risk. Stroke 2006; 37:2930-4.

van Rijn MJ, Schut AF, Aulchenko YS et al. Heritability of blood pressure traits and the genetic contribution to blood pressure variance explained by four blood-pressure-related genes. J Hypertens 2007; 25:565-70.

van Rijn-Bikker PC, Mairuhu G, van Montfrans GA et al. Genetic factors are relevant and independent determinants of antihypertensive drug effects in a multiracial population. Am J Hypertens 2009; 22:1295-302.

van Roij MH, Mizumoto S, Yamada S et al. Spondyloepiphyseal dysplasia, Omani type: further definition of the phenotype. Am J Med Genet A 2008; 146:2376-84.

van Rossum EF, Feelders RA, van den Beld AW et al. Association of the ER22/23EK polymorphism in the glucocorticoid receptor gene with survival and C-reactive protein levels in elderly men. Am J Med 2004; 117:158-62.

van Schaik RH. Cancer treatment and pharmacogenetics of cytochrome P450 enzymes. Invest New Drugs 2005; 23:513-22.

van Schaik RH. CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist Updat 2008; 11:77-98.

van Schaik RH, de Wildt SN, van Iperen NM, Uitterlinden AG, van den Anker JN, Lindemans J. CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians. Clin Chem 2000; 46:1834-6.

van Schaik RH, Kok M, Sweep FC et al. The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients. Pharmacogenomics 2011; 12:1137-46.

van Schie RM, Wessels JA, le Cessie S et al. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. Eur Heart J 2011; 32:1909-17.

van Swieten JC, Rosso SM, van Herpen E, Kamphorst W, Ravid R, Heutink P. Phenotypic variation in frontotemporal dementia and parkinsonism linked to chromosome 17. Dement Geriart Cogn Disord 2004; 17:261-4.

van Tilburg JH, Wijmenga C, van Bakel H, Rozeman L, Pearson PL, van Haeften TW. Relationship of beta2-adrenergic receptor polymorphism with obesity in type 2 diabetes. Diabetes Care 2003; 26:251-2.

van Tol HH, Wu CM, Guan HC et al. Multiple dopamine D4 receptor variants in the human population. Nature 1992; 358:149-52.

van Veen A, Wierenga EA, Westland R et al. Limited beta2-adrenoceptor haplotypes display different agonist mediated airway responses in asthmatics. Respir Res 2006; 7:19.

van Veen T, Nielsen J, Berkhof J et al. CCL5 and CCR5 genotypes modify clinical, radiological and pathological features of multiple sclerosis. J Neuroimmunol 2007; 190:157-64.

van Veldhuizen PJ, Reed G, Aggarwal A, Baranda J, Zulfiqar M, Williamson S. Docetaxel and ketoconazole in advanced hormone-refractory prostate carcinoma: a phase I and pharmacokinetic study. Cancer 2003; 98:1855-62.

van Waarde A, Rybczynska AA, Ramakrishnan N, Ishiwata K, Elsinga PH, Dierckx RA. Sigma receptors in oncology: therapeutic and diagnostic applications of sigma ligands. Curr Pharm Des 2010; 16:3519-37.

van Waterschoot RA, Eman RM, Wagenaar E et al. ABCC2, ABCC3, and ABCB1, but not CYP3A, protect against trabectedin-mediated hepatotoxicity. Clin Cancer Res 2009; 15:7616-23.

van Waterschoot RA, Lagas JS, Wagenaar E, Rosing H, Beijnen JH, Schinkel AH. Individual and combined roles of CYP3A, P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel. Int J Cancer 2010; 127:2959-64.

van Waterschoot RA, Rooswinkel RW, Sparidans RW, van Herwaarden AE, Beijnen JH, Schinkel AH. Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam. Drug Metab Dispos 2009; 37:2305-13.

van Waterschoot RA, Rooswinkel RW, Wagenaar E, van der Kruijssen CM, van Herwaarden AE, Schinkel AH. Intestinal cytochrome P450 3A plays an important role in the regulation of detoxifying systems in the liver. FASEB J 2009; 23:224-31.

van Waterschoot RA, Schinkel AH. A critical analysis of the interplay between cytochrome P450 3A and P-glycoprotein: recent insights from Knockout and transgenic mice. Pharmacol Rev 2011; 63:390-410.

van Waterschoot RA, ter Heine R, Wagenaar E et al. Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. Br J Pharmacol 2010; 160:1224-33.

van Wieren-de Wijer DB, Maitland-van der Zee AH, de Boer A et al. Interaction between the Gly460Trp alpha-adducin gene variant and diuretics on the risk of myocardial infarction. J Hypertens 2009; 27:61-8.

van Wieren-de Wijer DB, Maitland-van der Zee AH, de Boer A et al. Recruitment of participants through community pharmacies for a pharmacogenetic study of antihypertensive drug treatment. Pharm World Sci 2009; 31:158-64.

Vanakoski J, Mattila MJ, Seppälä T. Grapefruit juice does not enhance the effects of midazolam and triazolam in man. Eur J Clin Pharmacol 1996; 50:501-8.

Vanalstine MA, Hough LB. Effects of acetylenic epoxygenase inhibitors on recombinant cytochrome p450s. Drug Metab Dispos 2011; 39:1221-6.

Vance JE, Hayashi H. Formation and function of apolipoprotein E-containing lipoproteins in the nervous system. Biochim Biophys Acta 2010; 1801:806-18.

Vandel P, Haffen E, Nezelof S, Broly F, Kantelip JP, Sechter D. Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients. Hum Psychopharmacol 2004; 19:293-8.

Vandel S, Bertschy G, Baumann P et al. Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacol Res 1995; 31:347-53.

Vanden Bossche H, Ausma J, Bohets H et al. The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp. , and Microsporum canis. Antimicrob Agents Chemother 2004; 48:3272-8.

Vandenbergh DJ, O’Connor RJ, Grant MD et al. Dopamine receptor genes (DRD2, DRD3 and DRD4) and gene-gene interactions associated with smoking-related behaviors. Addict Biol 2007; 12:106-16.

Vandenbossche J, Huisman M, Xu Y, Sanderson-Bongiovanni D, Soons P. Loperamide and P-glycoprotein inhibition: assessment of the clinical relevance. J Pharm Pharmacol 2010; 62:401-12.

Vandenbrink BM, Foti RS, Rock DA, Wienkers LC, Wahlstrom JL. Evaluation of CYP2C8 inhibition in vitro: Utility of montelukast as a selective CYP2C8 probe substrate. Drug Metab Dispos 2011; 39:1546-54.

Vander Borght S, van Pelt J, van Malenstein H et al. Up-regulation of breast cancer resistance protein expression in hepatoblastoma following chemotherapy: A study in patients and in vitro. Hepatol Res 2008; 38:1112-21.

VanderVaart S, Berger H, Sistonen J et al. CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study. Ther Drug Monit 2011; 33:425-32.

VanderWel SN, Harvey PJ, McNamara DJ et al. Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4. J Med Chem 2005; 48:2371-87.

Vangsted AJ, Søeby K, Klausen TW et al. No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with multiple myeloma. BMC Cancer 2010; 10:404.

VanItallie TB. Gout: epitome of painful arthritis. Metabolism 2010; 59 Suppl 1:32-6.

Vannay A, Sziksz E, Prókai A et al. Increased expression of hypoxia-inducible factor 1alpha in coeliac disease. Pediatr Res 2010; 68:118-22.

Vannozzi F, Filipponi F, Di Paolo A et al. An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipients. Transplant Proc 2004; 36:2787-90.

Vanwert AL, Bailey RM, Sweet DH. Organic anion transporter 3 (Oat3/Slc22a8) knockout mice exhibit altered clearance and distribution of penicillin G. Am J Physiol Renal Physiol 2007; 293:1332-41.

Vanwert AL, Srimaroeng C, Sweet DH. Organic anion transporter 3 (oat3/slc22a8) interacts with carboxyfluoroquinolones, and deletion increases systemic exposure to ciprofloxacin. Mol Pharmacol 2008; 74:122-31.

Vanwijngaerden YM, Wauters J, Langouche L et al. Critical illness evokes elevated circulating bile acids related to altered hepatic transporter and nuclear receptor expression. Hepatology 2011. doi:10. 1002/hep. 24582.

Vanyukov MM, Moss HB, Gioio AE, Hughes HB, Kaplan BB, Tarter RE. An association between a microsatellite polymorphism at the DRD5 gene and the liability to substance abuse: pilot study. Behav Genet 1998; 28:75-82.

Vardeny O, Detry MA, Moran JJ, Johnson MR, Sweitzer NK. The beta2 adrenergic receptor Gln27Glu polymorphism affects insulin resistance in patients with heart failure: possible modulation by choice of beta blocker. J Cardiovasc Pharmacol 2008; 52:500-6.

Vardy ER, Rice PJ, Bowie PC, Holmes JD, Catto AJ, Hooper NM. Plasma angiotensin-converting enzyme in Alzheimer’s disease. J Alzheimers Dis 2009; 16:609-18.

Vargens DD, Neves RR, Bulzico DA et al. Association of the UGT1A1-53(TA)n polymorphism with L-thyroxine doses required for thyrotropin suppression in patients with differentiated thyroid cancer. Pharmacogenet Genomics 2011; 21:341-3.

Varges D, Jung K, Gawinecka J et al. Amyloid-β 1-42 levels are modified by apolipoprotein E ε4 in Creutzfeldt-Jakob disease in a similar manner as in Alzheimer’s disease. J Alzheimers Dis 2011; 23:717-26.

Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994; 56:601-7.

Varhe A, Olkkola KT, Neuvonen PJ. Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism. Br J Clin Pharmacol 1996; 41:319-23.

Varhe A, Olkkola KT, Neuvonen PJ. Diltiazem enhances the effects of triazolam by inhibiting its metabolism. Clin Pharmacol Ther 1996; 59:369-75.

Varis T, Backman JT, Kivistö KT, Neuvonen PJ. Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone. Clin Pharmacol Ther 2000; 67:215-21.

Varis T, Kaukonen KM, Kivistö KT, Neuvonen PJ. Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. Clin Pharmacol Ther 1998; 64:363-8.

Varis T, Kivistö KT, Backman JT, Neuvonen PJ. Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers. Pharmacol Toxicol 1999; 85:29-32.

Varis T, Kivistö KT, Neuvonen PJ. The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone. Eur J Clin Pharmacol 2000; 56:57-60.

Varlamov DA, Kudin AP, Vielhaber S et al. Metabolic consequences of a novel missense mutation of the mtDNA CO I gene. Hum Mol Genet 2002; 11:1797-805.

Varley CK. Sudden death related to selected tricyclic antidepressants in children: epidemiology, mechanisms and clinical implications. Paediatr Drugs 2001; 3:613-27.

Varma MV, Ambler CM, Ullah M et al. Targeting intestinal transporters for optimizing oral drug absorption. Curr Drug Metab 2010; 11:730-42.

Varsaldi F, Miglio G, Scordo MG et al. Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer’s disease patients. Eur J Clin Pharmacol 2006; 62:721-6.

Vasconcelos FC, Silva KL, Souza PS et al. Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients. Cytometry B Clin Cytom 2011; 80:158-66.

Vasilescu A, Terashima Y, Enomoto M et al. A haplotype of the human CXCR1 gene protective against rapid disease progression in HIV-1+ patients. Proc Natl Acad Sci USA 2007; 104:3354-9.

Vasilev NP, Julsing MK, Koulman A et al. Bioconversion of deoxypodophyllotoxin into epipodophyllotoxin in E. coli using human cytochrome P450 3A4. J Biotechnol 2006; 126:383-93.

Vassar R. The beta-secretase, BACE: a prime drug target for Alzheimer’s disease. J Mol Neurosci 2001; 17:157-70.

Vassar R. BACE1: the beta-secretase enzyme in Alzheimer’s disease. J. Mol. Neurosci 2004; 23:105-14.

Vassar R, Bennet BD, Babu-Khan S et al. b-Secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999; 286:735-41.

Vasseur F, Caeyseele T, Barat-Houari M et al. Concordance of two multiple analytical approaches demonstrate that interaction between BMI and ADIPOQ haplotypes is a determinant of LDL cholesterol in a general French population. J Hum Genet 2010; 55:227-31.

Vasseur F, Helbecque N, Dina C et al. Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes in French Caucasians. Hum Molec Genet 2002; 11:2607-14.

Vasseur F, Meyre D, Froguel P. Adiponectin, type 2 diabetes and the metabolic syndrome: lessons from human genetic studies. Expert Rev Mol Med 2006; 8:1-12.

Vatsis KP, Martell KJ, Weber WW. Diverse point mutations in the human gene for polymorphic N-acetyltransferase. Proc Natl Acad Sci USA 1991; 88:6333-7.

Vaury C, Lainé R, Noguiez P et al. Human glutathione S-transferase M1 null genotype is associated with a high inducibility of cytochrome P450 1A1 gene transcription. Cancer Res 1995; 55:5520-3.

Vautier S, Milane A, Fernandez C, Chacun H, Lacomblez L, Farinotti R. Role of two efflux proteins, ABCB1 and ABCG2 in blood-brain barrier transport of bromocriptine in a murine model of MPTP-induced dopaminergic degeneration. J Pharm Pharm Sci 2009; 12:199-208.

Vax VV, Bibi R, Diaz-Cano S et al. Activating point mutations in cyclin-dependent kinase 4 are not seen in sporadic pituitary adenomas, insulinomas or Leydig cell tumours. J Endocrinol 2003; 178:301-10.

Vaxillaire M, Dechaume A, Busiah K et al. New ABCC8 mutations in relapsing neonatal diabetes and clinical features. Diabetes 2007; 56:1737-41.

Vaxillaire M, Dina C, Lobbens S et al. Effect of common polymorphisms in the HNF4alpha promoter on susceptibility to type 2 diabetes in the French Caucasian population. Diabetologia 2005; 48:440-4.

Vaxillaire M, Froguel P. Monogenic diabetes in the young, pharmacogenetics and relevance to multifactorial forms of type 2 diabetes. Endocr Rev 2008; 29:254-64.

Veal GJ, Back DJ. Metabolism of zidovudine. Gen Pharmacol 1995; 26:1469-75.

Vecchione A, Baldassarre G, Ishii H et al. Fez1/Lzts1 absence impairs Cdk1/Cdc25C interaction during mitosis and predisposes mice to cancer development. Cancer Cell 2007; 11:275-89.

Vecsler M, Loebstein R, Almog S et al. Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. Thromb Haemost 2006; 95:205-11.

Veenstra DL, Blough DK, Higashi MK et al. CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clin Pharmacol Ther 2005; 77:353-64.

Veenstra DL, You JHS, Rieder MJ et al. Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet Genomics 2005; 15:687-91.

Veenstra-VanderWeele J, Anderson GM, Cook EH Jr. Pharmacogenetics and the serotonin system: initial studies and future directions. Eur J Pharmacol 2000; 410:165-81.

Veenstra-VanderWeele J, Kim SJ, Lord C et al. Transmission disequilibrium studies of the serotonin 5-HT2A receptor gene (HTR2A) in autism. Am J Med Genet 2002; 114:277-83.

Veenstra-VanderWeele J, Qaadir A, Palmer AA, Cook EH Jr, de Wit H. Association between the casein kinase 1 epsilon gene region and subjective response to D-amphetamine. Neuropsychopharmacology 2006; 31:1056-63.

Veeramah KR, Thomas MG, Weale ME et al. The potentially deleterious functional variant flavin-containing monooxygenase 2*1 is at high frequency throughout sub-Saharan Africa. Pharmacogenet Genomics 2008; 18:877-86.

Veeraputhiran M, Sundermeyer M. Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin. Clin Lung Cancer 2008; 9:232-4.

Vehof J, Risselada AJ, Al Hadithy AF et al. Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medication. Psychopharmacology 2011; 216:257-65.

Veiga L, Silva-Nunes J, Melão A, Oliveira A, Duarte L, Brito M. Q192R polymorphism of the paraoxonase-1 gene as a risk factor for obesity in Portuguese women. Eur J Endocrinol 2011; 164:213-8.

Veiga MI, Asimus S, Ferreira PE et al. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam. Eur J Clin Pharmacol 2009; 65:355-63.

Veinlichova A, Jancova P, Siller M et al. Effect of acetylcholinesterase oxime-type reactivators K-48 and HI-6 on human liver microsomal cytochromes P450 in vitro. Chem Biol Interact 2009; 180:449-53.

Veitch ZW, Guo B, Hembruff SL et al. Induction of 1C aldoketoreductases and other drug dose-dependent genes upon acquisition of anthracycline resistance. Pharmacogenet Genomics 2009; 19:477-88.

Velaparthi U, Saulnier MG, Wittman MD et al. Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one. Bioorg Med Chem Lett 2010; 20:3182-5.

Velaparthi U, Wittman M, Liu P et al. Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity. J Med Chem 2008; 51:5897-900.

Velati D, Viana M, Cresta S et al. 5-Hydroxytryptamine1B receptor and triptan response in migraine, lack of association with common polymorphisms. Eur J Pharmacol 2008; 580:43-7.

Veldhoen M, Hirota K, Westendorf AM et al. The aryl hdrocarbon receptor links T(H)17-cell-mediated autoimmunity to environmental toxins. Nature 2008; 453:106-9.

Veldhuis JD, Pincus SM, Garcia-Rudaz MC, Ropelato MG, Escobar ME, Barontini M. Disruption of the synchronous secretion of leptin, LH, and ovarian androgens in nonobese adolescents with the polycystic ovarian syndrome. J Clin Endocrinol Metab 2001; 86:3772-8.

Velez DR, Guruju M, Vinukonda G, Prater A, Kumar A, Williams SM. Angiotensinogen promoter sequence variants in essential hypertension. Am J Hypertens 2006; 19:1278-85.

Velykyĭ MM, Apukhovs’ka LI, Vasylevs’ka VM, Lotots’ka OIu, Besusiak AI, Khomenko AV. Features of cholecalciferol hydroxylation in the liver of rats in conditions of D-hypervitaminosis and activity of alpha-tocopherol. Ukr Biokhim Zh 2010; 82:67-74.

Vempati S, Reindl C, Kaza SK et al. Arginine 595 is duplicated in patients with acute leukemias carrying internal tandem duplications of FLT3 and modulates its transforming potential. Blood 2007; 110:686-94.

Vendramini AA, de Lábio RW, Rasmussen LT et al. Interleukin-8-251T > A, Interleukin-1α-889C > T and Apolipoprotein E polymorphisms in Alzheimer’s disease. Genet Mol Biol 2011; 34:1-5.

Venkatakrishnan K, Rader M, Ramanathan RK et al. Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: a prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study. Clin Ther 2009; 31:2444-58.

Venkatakrishnan K, von Moltke LL, Duan SX, Fleishaker JC, Shader RI, Greenblatt DJ. Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man. J Pharm Pharmacol 1998; 50:265-74.

Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs. J Clin Pharmacol 1999; 39:567-77.

Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000; 38:111-80.

Venkatakrishnan K, von Moltke LL, Obach RS, Greenblatt DJ. Microsomal binding of amitriptyline: effect on estimation of enzyme kinetic parameters in vitro. J Pharmacol Exp Ther 2000; 293:343-50.

Venkataramanan R, Ramachandran V, Komoroski BJ, Zhang S, Schiff PL, Strom SC. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab Dispos 2000; 28:1270-3.

Venkatesh P, Harisudhan T, Choudhury H, Mullangi R, Srinivas NR. Pharmacokinetics of etoposide in rats with uranyl nitrate (UN)-induced acute renal failure (ARF): optimization of the duration of UN dosing. Eur J Drug Metab Pharmacokinet 2007; 32:189-96.

Venner M, Peters J, Höhensteiger N et al. Concentration of the macrolide antibiotic tulathromycin in broncho-alveolar cells is influenced by comedication of rifampicin in foals. Naunyn Schmiedebergs Arch Pharmacol 2010; 381:161-9.

Ventura V, Solà J, Celma C, Peraire C, Obach R. In vitro metabolism of irosustat, a novel steroid sulfatase inhibitor: interspecies comparison, metabolite identification, and metabolic enzyme identification. Drug Metab Dispos 2011; 39:1235-46.

Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008; 64:1147-61.

Verdier MC, Bentué-Ferrer D, Tribut O; le groupe Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique. Therapeutic drug monitoring of zonisamide. Therapie 2010; 65:29-34.

Vergani D, Mieli-Vergani G. Aetiopathogenesis of autoimmune hepatitis. World J Gastroenterol 2008; 14:3306-12.

Vergeer M, Korporaal SJ, Franssen R et al. Genetic variant of the scavenger receptor BI in humans. N Engl J Med 2011; 364:136-45.

Verhoeven CH, van Munster TT, Groothuis GM, Vos RM, Rietjens IM. Identification of the human P450 enzymes involved in the in vitro metabolism of the synthetic steroidal hormones Org 4060 and Org 30659. Xenobiotica 2002; 32:109-18.

Verlaan M, Drenth JP, Truninger K et al. Polymorphisms of UDP-glucuronosyltransferase 1A7 are not involved in pancreatic diseases. J Med Genet 2005; 42:62.

Verma A, Piccoli DA, Bonilla E, Berry GT, DiMauro S, Moraes CT. A novel mitochondrial G8313A mutation associated with prominent initial gastrointestinal symptoms and progressive encephaloneuropathy. Pediatr Res 1997; 42:448-54.

Verma A, Prasad KN, Gupta RK et al. Toll-like receptor 4 polymorphism and its association with symptomatic neurocysticercosis. J Infect Dis 2010; 202:1219-25.

Verma MK, Miki Y, Sasano H. Aromatase in human lung carcinoma. Steroids 2011; 76:759-64.

Verma S, Li SH, Badiwala MV et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002; 105:1890-6.

Vermeir M, Hemeryck A, Cuyckens F et al. In vitro studies on the metabolism of trabectedin (Yondelis) in monkey and man, including human CYP reaction phenotyping. Biochem Pharmacol 2009; 77:1642-54.

Vermeir M, Naessens I, Remmerie B et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos 2008; 36:769-79.

Vermes A, Vermes I. Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors. Am J Cardiovasc Drugs 2004; 4:247-55.

Vermulst M, Wanagat J, Kujoth GC et al. DNA deletions and clonal mutations drive premature aging in mitochondrial mutator mice. Nat Genet 2008; 40:392-4.

Veronese L, Rautaureau J, Sadler BM et al. Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function. Antimicrob Agents Chemother 2000; 44:821-6.

Veronese ME, Doecke CJ, Mackenzie PI et al. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochem J 1993; 289:533-8.

Veronese ME, Miners JO, Rees DL, Birkett DJ. Tolbutamide hydroxylation in humans: lack of bimodality in 106 healthy subjects. Pharmacogenetics 1993; 3:86-93.

Veronese ML, Gillen LP, Burke JP et al. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. J Clin Pharmacol 2003; 43:831-9.

Veronese ML, Gillen LP, Dorval EP, Hauck WW, Waldman SA, Greenberg HE. Effect of mibefradil on CYP3A4 in vivo. J Clin Pharmacol 2003; 43:1091-100.

Veronese ML, Stevenson JP, Sun W et al. Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer. Eur J Cancer 2004; 40:508-14.

Verpillat P, Camuzat A, Hannequin D et al. Apolipoprotein E gene in frontotemporal dementia: an association study and metanalysis. Europ J Hum Genet 2002; 10:399-405.

Verpillat P, Camuzat A, Hannequin D et al. Association between the extended tau haplotype and frontotemporal dementia. Arch Neurol 2002; 59:935-9.

Verschuren L, Wielinga PY, van Duyvenvoorde W et al. A dietary mixture containing fish oil, resveratrol, lycopene, catechins, and vitamins e and C reduces atherosclerosis in transgenic mice. J Nutr 2011; 141:863-9.

Versiani MA, Diyabalanage T, Ratnayake R et al. Flavonoids from eight tropical plant species that inhibit the multidrug resistance transporter ABCG2. J Nat Prod 2011; 74:262-6.

Versini A, Ramoz N, Le Strat Y et al. Estrogen receptor 1 gene (ESR1) is associated with restrictive anorexia nervosa. Neuropsychopharmacology 2010; 35:1818-25.

Verslycke T, Goldstone JV, Stegeman JJ. Isolation and phylogeny of novel cytochrome P450 genes from tunicates (Ciona spp. ): a CYP3 line in early deuterostomes? Mol Phylogenet Evol 2006; 40:760-71.

Versmissen J, Oosterveer DM, Yazdanpanah M et al. A frequent variant in the ABCA1 gene is associated with increased coronary heart disease risk and a better response to statin treatment in familial hypercholesterolemia patients. Eur Heart J 2011; 32:469-75.

Verstuyft C, Morin S, Robert A et al. Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers. Pharmacogenetics 2001; 11:735-7.

Verstuyft C, Strabach S, El-Morabet H et al. Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. Clin Pharmacol Ther 2003; 73:51-60.

Vets E, Rossignol JF, Jackson AS. Effects of nitazoxanide on pharmacokinetics and pharmacodynamics of a single dose of warfarin. Am J Health Syst Pharm 2009; 66:838-42.

Veuger MJ, Honders MW, Landegent JE, Willemze R, Barge RM. A novel RT-PCR-based protein activity truncation assay for direct assessment of deoxycytidine kinase in small numbers of purified leukemic cells. Leukemia 2000; 14:1678-84.

Veuger MJ, Honders MW, Landegent JE, Willemze R, Barge RM. High incidence of alternatively spliced forms of deoxycytidine kinase in patients with resistant acute myeloid leukemia. Blood 2000; 96:1517-24.

Vevelstad M, Pettersen S, Tallaksen C, Brørs O. O-demethylation of codeine to morphine inhibited by low-dose levomepromazine. Eur J Clin Pharmacol 2009; 65:795-801.

Vezeridis AM, Chroni A, Zannis VI. Domains of apoE4 required for the biogenesis of apoE-containing HDL. Ann Med 2011; 43:302-11.

Viaggi C, Vaglini F, Pardini C, Caramelli A, Corsini GU. MPTP-induced model of Parkinson’s disease in cytochrome P450 2E1 knockout mice. Neuropharmacology 2009; 56:1075-81.

Viale M, Cordazzo C, de Totero D et al. Inhibition of MDR1 activity and induction of apoptosis by analogues of nifedipine and diltiazem: an in vitro analysis. Invest New Drugs 2011; 29:98-109.

Viana AC, Kim YJ, Curtis KM et al. Association of haplotypes in the CXCR2 gene with periodontitis in a Brazilian population. DNA Cell Biol 2010; 29:191-200.

Vianna-Jorge R, Perini JA, Rondinelli E, Suarez-Kurtz G. CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. Clin Pharmacol Ther 2004; 76:18-26.

Vibhuti A, Arif E, Mishra A et al. CYP1A1, CYP1A2 and CYBA gene polymorphisms associated with oxidative stress in COPD. Clin Chim Acta 2010; 411:474-80.

Vicari-Christensen M, Repper S, Basile S, Young D. Tacrolimus: review of pharmacokinetics, pharmacodynamics, and pharmacogenetics to facilitate practitioners’ understanding and offer strategies for educating patients and promoting adherence. Prog Transplant 2009; 19:277-84.

Vicens M, Macias RI, Briz O et al. Inhibition of the intestinal absorption of bile acids using cationic derivatives: mechanism and repercussions. Biochem Pharmacol 2007; 73:394-404.

Vickers AE, Meyer E, Dannecker R, Keller B, Tynes RE, Maurer G. Human liver cytochrome P4503A biotransformation of the cyclosporin derivative SDZ IMM 125. Drug Metab Dispos 1995; 23:321-6.

Vickers AE, Sinclair JR, Zollinger M et al. Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab Dispos 1999; 27:1029-38.

Vidali M, Occhino G, Ivaldi A et al. Detection of auto-antibodies against cytochrome P4502E1 (CYP2E1) in chronic hepatitis C. J Hepatol 2007; 46:605-12.

Vidaurreta M, Sánchez-Muñoz R, Veganzones S et al. Vascular endothelial growth factor gene polymorphisms in patients with colorectal cancer. Rev Esp Enferm Dig 2010; 102:20-31.

Videmann B, Mazallon M, Prouillac C, Delaforge M, Lecoeur S. ABCC1, ABCC2 and ABCC3 are implicated in the transepithelial transport of the myco-estrogen zearalenone and its major metabolites. Toxicol Lett 2009; 190:215-23.

Vidyashankar S, Sambaiah K, Srinivasan K. Dietary garlic and onion reduce the incidence of atherogenic diet-induced cholesterol gallstones in experimental mice. Br J Nutr 2009; 101:1621-9.

Vieland VJ, Huang Y, Bartlett C, Davies TF, Tomer Y. A multilocus model of the genetic architecture of autoimmune thyroid disorder, with clinical implications. Am J Hum Genet 2008; 82:1349-56.

Viemari JC, Hilaire G. Monoamine oxidase A-deficiency and noradrenergic respiratory regulations in neonatal mice. Neurosci Lett 2003; 340:221-4.

Vietri M, de Santi C, Pietrabissa A, Mosca F, Pacifici GM. Inhibition of human liver phenol sulfotransferase by nonsteroidal anti-inflammatory drugs. Eur J Clin Pharmacol 2000; 56:81-7.

Vignati L, Turlizzi E, Monaci S, Grossi P, Kanter R, Monshouwer M. An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics. Toxicology 2005; 216:154-67.

Vignati LA, Bogni A, Grossi P, Monshouwer M. A human and mouse pregnane X receptor reporter gene assay in combination with cytotoxicity measurements as a tool to evaluate species-specific CYP3A induction. Toxicology 2004; 199:23-33.

Vignaud A, Fougerousse F, Mouisel E et al. Genetic inactivation of acetylcholinesterase causes functional and structural impairment of mouse soleus muscles. Cell Tissue Res 2008; 333:289-96.

Viikki M, Kampman O, Illi A et al. TPH1 218A/C polymorphism is associated with major depressive disorder and its treatment response. Neurosci Lett 2010; 468:80-4.

Vijayakrishnan J, Houlston RS. Candidate gene association studies and risk of childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Haematologica 2010; 95:1405-14.

Vikhanskaya F, Siddique MM, Kei Lee M, Broggini M, Sabapathy K. Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs. Clin Cancer Res 2005; 11:4348-56.

Vikman S, Brena RM, Armstrong P, Hartiala J, Stephensen CB, Allayee H. Functional analysis of 5-lipoxygenase promoter repeat variants. Hum Mol Genet 2009; 18:4521-9.

Vila L, Liu H, Al-Quran SZ, Coco DP, Dong HJ, Liu C. Identification of c-kit gene mutations in primary adenoid cystic carcinoma of the salivary gland. Mod Pathol 2009; 22:1296-302.

Vilar R, Coelho H, Rodrigues E et al. Association of A313 G polymorphism (GSTP1*B) in the glutathione-S-transferase P1 gene with sporadic Parkinson’s disease. Eur J Neurol 2007; 14:156-61.

Vilas-Zornoza A, Agirre X, Martín-Palanco V et al. Frequent and simultaneous epigenetic inactivation of TP53 pathway genes in acute Lymphoblastic Leukemia. PLoS One 2011. doi:10. 1371/journal. pone. 0017012.

Villafuerte SM, Vallabhaneni K, Sliwerska E, McMahon FJ, Young EA, Burmeister M. SSRI response in depression may be influenced by SNPs in HTR1B and HTR1A. Psychiatr Genet 2009; 19:281-91.

Villagra D, Duconge J, Windemuth A et al. CYP2C9 and VKORC1 genotypes in Puerto Ricans: A case for admixture-matching in clinical pharmacogenetic studies. Clin Chim Acta 2010; 411:1306-11.

Villanova FE, Andrade E, Leal E et al. Erection induced by Tx2-6 toxin of Phoneutria nigriventer spider: expression profile of genes in the nitric oxide pathway of penile tissue of mice. Toxicon 2009; 54:793-801.

Villanueva SS, Arias A, Ruiz ML et al. Induction of intestinal multidrug resistance-associated protein 2 by glucagon-like Peptide 2 in the rat. J Pharmacol Exp Ther 2010; 335:332-41.

Villard PH, Barlesi F, Armand M et al. CYP1A1 induction in the colon by serum: involvement of the PPARα pathway and evidence for a new specific human PPREα site. PLoS One 2011. doi:10. 1371/journal. pone. 0014629.

Villasana LE, Benice TS, Raber J. Long-term effects of (56)Fe irradiation on spatial memory of mice: role of sex and apolipoprotein e isoform. Int J Radiat Oncol Biol Phys 2011; 80:567-73.

Villemagne VL, Pike KE, Chételat G et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol 2011; 69:181-92.

Villeneuve L, Girard H, Fortier LC, Gagné JF, Guillemette C. Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J Pharmacol Exp Ther 2003; 307:117-28.

Villikka K, Kivistö KT, Backman JT, Olkkola KT, Neuvonen PJ. Triazolam is ineffective in patients taking rifampin. Clin Pharmacol Ther 1997; 61:8-14.

Villikka K, Kivistö KT, Lamberg TS, Kantola T, Neuvonen PJ. Concentrations and effects of zopiclone are greatly reduced by rifampicin. Br J Clin Pharmacol 1997; 43:471-4.

Villikka K, Kivistö KT, Luurila H, Neuvonen PJ. Rifampin reduces plasma concentrations and effects of zolpidem. Clin Pharmacol Ther 1997; 62:629-34.

Villikka K, Kivistö KT, Mäenpää H, Joensuu H, Neuvonen PJ. Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. Clin Pharmacol Ther 1999; 66:589-93.

Villikka K, Kivistö KT, Neuvonen PJ. The effect of dexamethasone on the pharmacokinetics of triazolam. Pharmacol Toxicol 1998; 83:135-8.

Villikka K, Kivistö KT, Neuvonen PJ. The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron. Clin Pharmacol Ther 1999; 65:377-81.

Villikka K, Varis T, Backman JT, Neuvonen PJ, Kivistö KT. Effect of methylprednisolone on CYP3A4-mediated drug metabolism in vivo. Eur J Clin Pharmacol 2001; 57:457-60.

Villuendas G, San Millán JL, Sancho J, Escobar-Morreale HF. The -597 G→A and -174 G→C polymorphisms in the promoter of the IL-6 gene are associated with hyperandrogenism. J Clin Endocrinol Metab 2002; 87:1134-41.

Vimaleswaran KS, Zhao JH, Wainwright NW, Surtees PG, Wareham NJ, Loos RJ. Association between serotonin 5-HT-2C receptor gene (HTR2C) polymorphisms and obesity- and mental health-related phenotypes in a large population-based cohort. Int J Obes 2010; 34:1028-33.

Vinayagamoorthy N, Krishnamurthi K, Devi SS et al. Genetic polymorphism of CYP2D6*2 C→T 2850, GSTM1, NQO1 genes and their correlation with biomarkers in manganese miners of Central India. Chemosphere 2010; 81:1286-91.

Vincent B, Checler F. α-Secretase in Alzheimer’s disease and beyond: Mechanistic, regulation and function in the shedding of membrane proteins. Curr Alzheimer Res 2012; 9:140-56.

Vincent B, Govitrapong P. Activation of the α-secretase processing of AβPP as a therapeutic approach in Alzheimer’s disease. J Alzheimers Dis 2011; 24 Suppl 2:75-94.

Vincent F, Bonnin P, Clemessy M et al. Angiotensinogen delays angiogenesis and tumor growth of hepatocarcinoma in transgenic mice. Cancer Res 2009; 69:2853-60.

Vincent SH, Reed JR, Bergman AJ et al. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. Drug Metab Dispos 2007; 35:533-8.

Vinholt P, Poulsen TS, Korsholm L et al. The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease. Thromb Haemost 2005; 94:438-43.

Vink JM, Smit AB, de Geus EJ et al. Genome-wide association study of smoking initiation and current smoking. Am J Hum Genet 2009; 84:367-79.

Vionnet N, Tregouët D, Kazeem G et al. Analysis of 14 candidate genes for diabetic nephropathy on chromosome 3q in European populations: strongest evidence for association with a variant in the promoter region of the adiponectin gene. Diabetes 2006; 55:3166-74.

Virgo BB. Effects of somatostatin and testosterone on the hepatic monooxygenase system in castrated male rats. Drug Metab Dispos 1985; 13:9-13.

Visavadiya NP, Li Y, Wang S. High glucose upregulates upstream stimulatory factor 2 in human renal proximal tubular cells through angiotensin II-dependent activation of CREB. Nephron Exp Nephrol 2011; 117:62-70.

Visser LE, Trienekens PH, de Smet PA et al. Patients with an ApoE epsilon4 allele require lower doses of coumarin anticoagulants. Pharmacogenet Genomics 2005; 15:69-74.

Visser LE, van Schaik RH, van Vliet M et al. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Thromb Haemost 2004; 92:61-6.

Visser LE, van Vliet M, van Schaik RH et al. The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics 2004; 14:27-33.

Vissing J, Ravn K, Danielsen ER et al. Multiple mtDNA deletions with features of MNGIE. Neurology 2002; 59:926-9.

Vitali A, Piccini A, Borghi R et al. Soluble amyloid beta-protein in increased in frontotemporal dementia with tau gene mutations. J Alzheimer Dis 2004; 6:45-51.

Vitelli F, Piccini M, Caroli F et al. Identification and characterization of a highly conserved protein absent in the Alport syndrome (A), mental retardation (M), midface hypoplasia (M), and elliptocytosis (E) contiguous gene deletion syndrome (AMME). Genomics 1999; 55:335-40.

Vitezica ZG, Milpied B, Lonjou C et al. HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS 2008; 22:540-1.

Vizziano-Cantonnet D, Anglade I, Pellegrini E et al. Sexual dimorphism in the brain aromatase expression and activity, and in the central expression of other steroidogenic enzymes during the period of sex differentiation in monosex rainbow trout populations. Gen Comp Endocrinol 2011; 170:346-55.

Vlad SC, Miller DR, Kowall NW, Felson DT. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 2008; 70:1672-7.

Vlaming ML, Pala Z, van Esch A et al. Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo. Clin Cancer Res 2009; 15:3084-93.

Vlaming ML, Pala Z, van Esch A et al. Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate. Clin Cancer Res 2008; 14:8152-60.

Vlaming ML, van Esch A, Pala Z et al. Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo. Mol Cancer Ther 2009; 8:3350-9.

Vlaming ML, van Esch A, van de Steeg E et al. Impact of Abcc2 (Mrp2), Abcc3 (Mrp3) and Abcg2 (Bcrp1) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate. Drug Metab Dispos 2011; 39:1338-44.

Voets M, Antes I, Scherer C et al. Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis. J Med Chem 2005; 48:6632-42.

Voets M, Antes I, Scherer C et al. Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis. J Med Chem 2006; 49:2222-31.

Vogel G. Tau protein mutations confirmed as neuron killers. Science 1998; 280:1524-5.

Vogel P, Read R, Hansen G et al. Pathology of congenital generalized lipodystrophy in Agpat2 -/-Mice. Vet Pathol 2011; 48:642-54.

Vogel U, Christensen J, Nexø BA, Wallin H, Friis S, Tjønneland A. Peroxisome proliferator-activated [corrected] receptor-gamma2 [corrected] Pro12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes. Carcinogenesis 2007; 28:427-34.

Vogel U, Overvad K, Wallin H et al. Combinations of polymorphisms in XPD, XPC and XPA in relation to risk of lung cancer. Cancer Lett 2005; 222:67-74.

Vogel U, Segel S, Dethlefsen C et al. Associations between COX-2 polymorphisms, blood cholesterol and risk of acute coronary syndrome. Atherosclerosis 2010; 209:155-62.

Vogler M, Dickens D, Dyer MJ, Owen A, Pirmohamed M, Cohen GM. The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein. Biochem Biophys Res Commun 2011; 408:344-9.

Vogt J, Harrison BJ, Spearman H et al. Mutation analysis of CHRNA1, CHRNB1, CHRND, and RAPSN genes in multiple pterygium syndrome/fetal akinesia patients. Am J Hum Genet 2008; 82:222-7.

Vohl MC, Lepage P, Gaudet D et al. Molecular scanning of the human PPARa gene: association of the L162v mutation with hyperapobetalipoproteinemia. J Lipid Res 2000; 41:945-52.

Voice MW, Zhang Y, Wolf CR, Burchell B, Friedberg T. Effects of human cytochrome b5 on CYP3A4 activity and stability in vivo. Arch Biochem Biophys 1999; 366:116-24.

Voight BF, Scott LJ, Steinthorsdottir V et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 2010; 42:579-89.

Voigt C, Ball GF, Balthazart J. Effects of sex steroids on aromatase mRNA expression in the male and female quail brain. Gen Comp Endocrinol 2011; 170:180-8.

Voineskos AN, Lerch JP, Felsky D et al. The brain-derived neurotrophic factor Val66Met polymorphism and prediction of neural risk for Alzheimer disease. Arch Gen Psychiatry 2011; 68:198-206.

Voirol P, Jonzier-Perey M, Porchet F et al. Cytochrome P-450 activities in human and rat brain microsomes. Brain Res 2000; 855:235-43.

Volak LP, Court MH. Role for protein kinase C delta in the functional activity of human UGT1A6: implications for drug-drug interactions between PKC inhibitors and UGT1A6. Xenobiotica 2010; 40:306-18.

Volak LP, Ghirmai S, Cashman JR, Court MH. Curcuminoids inhibit multiple human cytochromes P450, UDP-glucuronosyltransferase, and sulfotransferase enzymes, whereas piperine is a relatively selective CYP3A4 inhibitor. Drug Metab Dispos 2008; 36:1594-605.

Volcik KA, Blanton SH, Northrup H. Examinations of methylenetetrahydrofolate reductase C677T and A1298C mutations-and in utero viability. Am J Hum Genet 2001; 69:1150-3.

Volk EL, Schneider E. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res 2003; 63:5538-43.

Volkova M, Palmeri M, Russell KS, Russell RR. Activation of the aryl hydrocarbon receptor by doxorubicin mediates cytoprotective effects in the heart. Cardiovasc Res 2011; 90:305-14.

Volotinen M, Hakkola J, Pelkonen O, Vapaatalo H, Mäenpää J. Metabolism of ophthalmic timolol: new aspects of an old drug. Basic Clin Pharmacol Toxicol 2011; 108:297-303.

Volotinen M, Turpeinen M, Tolonen A, Uusitalo J, Mäenpää J, Pelkonen O. Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. Drug Metab Dispos 2007; 35:1135-41.

Volland C, Benet LZ. In vitro enantioselective glucuronidation of fenoprofen. Pharmacology 1991; 43:53-60.

von Ahsen N, Richter M, Grupp C, Ringe B, Oellerich M, Armstrong VW. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin Chem 2001; 47:1048-52.

von Ahsen N, Tzvetkov M, Karunajeewa HA et al. CYP2D6 and CYP2C19 in Papua New Guinea: High frequency of previously uncharacterized CYP2D6 alleles and heterozygote excess. Int J Mol Epidemiol Genet 2010; 1:310-9.

von Bahr C, Movin G, Nordin C et al. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 1991; 49:234-40.

von Bahr-Lindstrom H, Hoog JO, Heden LO et al. cDNA and protein structure for the alpha subunit of human liver alcohol dehydrogenase. Biochemistry 1986; 25:2465-70.

von Beckerath N, von Beckerath O, Koch W, Eichinger M, Schömig A, Kastrati A. P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. Blood Coagul Fibrinolysis 2005; 16:199-204.

von Bubnoff N, Manley PW, Mestan J, Sanger J, Peschel C, Duyster J. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood 2006; 108:1328-33.

von Eckardstein A, Sibler RA. Possible contributions of lipoproteins and cholesterol to the pathogenesis of diabetes mellitus type 2. Curr Opin Lipidol 2011; 22:26-32.

von Krogh K, Harjen H, Almås C et al. The effect of valproate and levetiracetam on steroidogenesis in forskolin-stimulated H295R cells. Epilepsia 2010; 51:2280-8.

von Moltke LL, Greenblatt DJ, Ciraulo DA et al. Appetite suppressant drugs as inhibitors of human cytochromes P450: in vitro inhibition of P450-2D6 by D- and L-fenfluramine, but not phentermine. J Clin Psychopharmacol 1998; 18:338-41.

von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995; 15:125-31.

von Moltke LL, Greenblatt DJ, Giancarlo GM, Granda BW, Harmatz JS, Shader RI. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos 2001; 29:1102-9.

von Moltke LL, Greenblatt DJ, Granda BW et al. Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J Clin Pharmacol 2001; 41:85-91.

von Moltke LL, Greenblatt DJ, Grassi JM et al. Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. J Pharm Pharmacol 1998; 50:997-1004.

von Moltke LL, Tran TH, Cotreau MM, Greenblatt DJ. Unusually low clearance of two CYP3A substrates, alprazolam and trazodone, in a volunteer subject with wild-type CYP3A4 promoter region. J Clin Pharmacol 2000; 40:200-4.

von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M, Kivistö KT. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther 2004; 75:172-83.

von Richter O, Pitarque M, Rodríguez-Antona C et al. Polymorphic NF-Y dependent regulation of human nicotine C-oxidase (CYP2A6). Pharmacogenetics 2004; 14:369-79.

von Rosensteil NA, Adam D. Macrolide antibacterials. Drug interactions of clinical significance. Drug Saf 1995; 13:105-22.

von Schnakenburg C, Rumsby G. Primary hyperoxaluria type 1: a cluster of new mutations in exon 7 of the AGXT gene. J Med Genet 1997; 34:489-92.

von Schnakenburg C, Rumsby G. Identification of new mutations in primary hyperoxaluria type 1 (PH1). J Nephrol 1998; 11:15-7.

von Vietinghoff S, Koltsova EK, Mestas J, Diehl CJ, Witztum JL, Ley K. Mycophenolate mofetil decreases atherosclerotic lesion size by depression of aortic T-lymphocyte and interleukin-17-mediated macrophage accumulation. J Am Coll Cardiol 2011; 57:2194-204.

von Vietinghoff S, Ley K. Interleukin 17 in vascular inflammation. Cytokine Growth Factor Rev 2010; 21:463-9.

Voncken JW, Roelen BAJ, Roefs M et al. Rnf2 (Ring1b) deficiency causes gastrulation arrest and cell cycle inhibition. Proc Nat Acad Sci USA 2003; 100:2468-73.

Vonlaufen A, Wilson JS, Pirola RC, Apte MV. Role of alcohol metabolism in chronic pancreatitis. Alcohol Res Health 2007; 30:48-54.

Voora D, Koboldt DC, King CR et al. A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther 2010; 87:445-51.

Voora D, Shah SH, Reed CR et al. Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response. Circ Cardiovasc Genet 2008; 1:100-6.

Voora D, Shah SH, Spasojevic I et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009; 54:1609-16.

Voorman RL, Maio SM, Hauer MJ, Sanders PE, Payne NA, Ackland MJ. Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: probable involvement of CYP2D6 and CYP3A. Drug Metab Dispos 1998; 26:631-9.

Voorman RL, Maio SM, Payne NA, Zhao Z, Koeplinger KA, Wang X. Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A. J Pharmacol Exp Ther 1998; 287:381-8.

Voorman RL, Payne NA, Wienkers LC, Hauer MJ, Sanders PE. Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6. Drug Metab Dispos 2001; 29:41-7.

Vorbach C, Scriven A, Capecchi MR. The housekeeping gene xanthine oxidoreductase is necessary for milk fat droplet enveloping and secretion: gene sharing in the lactating mammary gland. Genes Dev 2002; 16:3233-5.

Vormfelde SV, Burckhardt G, Zirk A, Wojnowski L, Brockmöller J. Pharmacogenomics of diuretic drugs: data on rare monogenic disorders and on polymorphisms and requirements for further research. Pharmacogenomics 2003; 4:701-34.

Vormfelde SV, Engelhardt S, Zirk A et al. CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. Clin Pharmacol Ther 2004; 76:557-66.

Vormfelde SV, Sehrt D, Bolte D, Pahl S, Tzvetkov M, Brockmöller J. Hydrochlorothiazide efficacy and polymorphisms in ACE, ADD1 and GNB3 in healthy, male volunteers. Eur J Clin Pharmacol 2006; 62:195-201.

Vorob’eva NM, Panchenko EP, Dobrovol’skiĭ AB et al. Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in moscow population: effects on stability of anticoagulant therapy and frequency of hemorrhage. Ter Arkh 2011; 83:59-65.

Vos MD, Scott FM, Iwai N, Treston AM. Expression in human lung cancer cell lines of genes of prohormone processing and the neuroendocrine phenotype. J Cell Biochem Suppl 1996; 24:257-68.

Vos RM, Krebbers SF, Verhoeven CH, Delbressine LP. The in vivo human metabolism of tibolone. Drug Metab Dispos 2002; 30:106-12.

Vosges M, Le Page Y, Chung BC et al. 17alpha-ethinylestradiol disrupts the ontogeny of the forebrain GnRH system and the expression of brain aromatase during early development of zebrafish. Aquat Toxicol 2010; 99:479-91.

Voso MT, Fabiani E, D’Alo’ F et al. Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes. Ann Oncol 2007; 18:1523-8.

Vossen M, Sevestre M, Niederalt C, Jang IJ, Willmann S, Edginton AN. Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models. Theor Biol Med Model 2007; 4:13.

Vottero A, Kino T, Combe H, Lecomte P, Chrousos GP. A novel, C-terminal dominant negative mutation of the GR causes familial glucocorticoid resistance through abnormal interactions with p160 steroid receptor coactivators. J Clin Endocrinol Metab 2002; 87:2658-67.

Vouk K, Smuc T, Guggenberger C et al. Novel estrogen-related genes and potential biomarkers of ovarian endometriosis identified by differential expression analysis. J Steroid Biochem Mol Biol 2011; 125:231-42.

Vourvahis M, Gleave M, Nedderman AN et al. Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]Lersivirine to healthy volunteers. Drug Metab Dispos 2010; 38:789-800.

Vourvahis M, Kashuba AD. Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir. Pharmacotherapy 2007; 27:888-909.

Voynow JA, Fischer BM, Zheng S et al. NAD(P)H quinone oxidoreductase 1 is essential for ozone-induced oxidative stress in mice and humans. Am J Respir Cell Mol Biol 2009; 41:107-13.

Vrba J, Vrublova E, Modriansky M, Ulrichova J. Protopine and allocryptopine increase mRNA levels of cytochromes P450 1A in human hepatocytes and HepG2 cells independently of AhR. Toxicol Lett 2011; 203:135-41.

Vreken P, van Kuilenburg ABP, Meinsma R, van Gennip AH. Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W. Hum Genet 1997; 101:333-8.

Vrijenhoek T, Buizer-Voskamp JE, van der Stelt I et al. Recurrent CNVs disrupt three candidate genes in schizophrenia patients. Am J Hum Genet 2008; 83:504-10.

Vrzal R, Kubesova K, Pavek P, Dvorak Z. Benzodiazepines medazepam and midazolam are activators of pregnane X receptor and weak inducers of CYP3A4: investigation in primary cultures of human hepatocytes and hepatocarcinoma cell lines. Toxicol Lett 2010; 193:183-8.

Vuilleumier N, Rossier MF, Chiappe A et al. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol 2006; 62:423-9.

Vyas PM, Roychowdhury S, Khan FD et al. Enzyme-mediated protein haptenation of dapsone and sulfamethoxazole in human keratinocytes: I. Expression and role of cytochromes P450. J Pharmacol Exp Ther 2006; 319:488-96.

Vyhlidal CA, Gaedigk R, Leeder JS. Nuclear receptor expression in fetal and pediatric liver: correlation with CYP3A expression. Drug Metab Dispos 2006; 34:131-7.